The 2013 study by Eckert, White, Jordan, Malhotra and Wellman quantified the four key phenotypic causes of obstructive sleep apnea (OSA) — passive upper-airway collapsibility (PcritP_{crit}), arousal threshold, loop gain, and genioglossus muscle responsiveness — and proposed the PALM scale to guide mechanism-targeted therapy. Its authors flagged five linked unresolved issues: trait distributions in untreated, REM-sleep, and longitudinally followed patients; generalizability to nonobese populations; simplified single-night phenotyping methods suitable for routine clinical practice; quantification of additional protective or maladaptive physiologic contributors; and adequately powered, mechanism-targeted intervention trials testing whether phenotyping improves therapy selection. Thirteen years of follow-up work has validated non-invasive polysomnographic endotyping at research level, phenotyped community and nonobese cohorts, and produced multiple positive phase-2 pharmacotherapy trials, but no prespecified phenotype-selection trial has been completed, and a 2025 American Thoracic Society research statement still lists clinical translation of endophenotyping (validation, cutoffs, generalizability, clinical utility) as open research priorities. The problem therefore remains open, with a precise surviving core: clinical-grade endotyping standards and a demonstrated, adequately powered, phenotype-guided selection benefit for nonanatomic therapies.

Background

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder in which the pharyngeal airway repetitively narrows or collapses during sleep, producing apneas, hypopneas, and oxygen desaturations; its severity is conventionally indexed by the apnea-hypopnea index (AHI), the number of breathing interruptions per hour of sleep. The first-line treatment, continuous positive airway pressure (CPAP), pneumatically splints the airway but is poorly tolerated or abandoned by roughly half of patients who try it, which motivated a search for treatments aimed at individual causal mechanisms rather than anatomy alone. Four measurable physiologic traits jointly determine whether the airway collapses during sleep: (1) passive pharyngeal collapsibility, quantified by the critical closing pressure (PcritP_{crit}), the nasal pressure at which the airway collapses when dilator muscles are passive — higher (less negative) values mean a floppier airway; (2) the arousal threshold, the depth of respiratory effort needed to trigger a cortical awakening — a low threshold truncates the ventilatory recruitment that would reopen the airway; (3) loop gain, an engineering-style dimensionless measure of ventilatory control stability — a high loop gain means the chemoreflex feedback loop overcorrects disturbances, driving self-sustaining breathing oscillations; and (4) genioglossus (tongue) muscle responsiveness, the ability of the main pharyngeal dilator muscle to increase its activity in response to the negative airway pressure of an incipient collapse. In 2013 Eckert, White, Jordan, Malhotra and Wellman measured all four traits with gold-standard techniques (CPAP pressure manipulations, epiglottic pressure catheters, diaphragm and genioglossus electromyography) across 75 participants over three nights each. They found striking heterogeneity: although the airway was on average more collapsible in OSA, 19% of patients had a relatively noncollapsible airway in which nonanatomic traits (particularly high loop gain) dominated, 69% of patients had one or more nonanatomic abnormality, and 56% had nonanatomic traits playing an important role. They distilled this into the PALM scale (Passive anatomy, Arousal threshold, Loop gain, Muscle responsiveness), a three-category framework intended to guide selection of therapies aimed at specific mechanisms — for example supplemental oxygen to reduce loop gain, hypnotic agents to raise a low arousal threshold, or hypoglossal nerve stimulation to restore muscle function — instead of the one-size-fits-all CPAP pathway. Crucially, the study was performed in CPAP-compliant patients during non-REM sleep, and the authors identified what would be required before PALM-based personalization could become clinical reality. Since 2013, several developments reshaped the field: non-invasive estimation of the traits from routine polysomnography (the multi-channel sleep study used in clinical diagnostics) was validated against gold-standard measurements (Sands et al. 2018, doi:10.1164/rccm.201707-1435OC); endotypic traits were measured at scale in community cohorts such as the Multi-Ethnic Study of Atherosclerosis; trait-based prediction of response to oxygen therapy and hypoglossal nerve stimulation was demonstrated in secondary analyses; and a wave of phase-2 pharmacotherapy trials (atomoxetine plus oxybutynin, aroxybutynin plus atomoxetine, sulthiame, acetazolamide combinations) produced positive results — though in patients enrolled without endotype-based selection. An official American Thoracic Society research statement in 2025 and recent reviews (Thorax 2023, Respirology 2026) agree that the field is mid-translation: measurement methods exist for research, but clinical standards, cutoffs, generalizability, and — above all — prespecified phenotype-stratified trial evidence of selection benefit are still missing.

Problem Statement

The 2013 PALM study left five linked questions that jointly define whether phenotypic-cause characterization of obstructive sleep apnea can be translated into mechanism-targeted clinical care, and all remain open in whole or in part. (1) Trait distributions in the populations and states where OSA is actually managed: how do the four measured traits — passive pharyngeal collapsibility (PcritP_{crit}, the nasal pressure at which the airway collapses when dilator muscles are passive), genioglossus (tongue dilator) muscle responsiveness, arousal threshold (the depth of respiratory effort needed to trigger a cortical awakening), and loop gain (the gain of the chemoreflex feedback loop that controls breathing during sleep, where high values drive self-sustaining oscillations) — distribute in untreated patients and in patients noncompliant with continuous positive airway pressure (CPAP, the pneumatic-splint standard therapy; the original cohort was CPAP-compliant), how do the traits behave in rapid-eye-movement (REM) sleep (the original measurements were made in non-REM sleep only), and how do they change over time with aging, sex, intermittent hypoxia, sleep deprivation, or CPAP treatment itself? (2) Generalizability to nonobese patients: what are the trait distributions in nonobese OSA, given the original cohort was predominantly obese? (3) Measurement translation: can simplified, single-night methods that reliably estimate the PALM traits (the four traits above, named for the Passive anatomy–Arousal threshold–Loop gain–Muscle responsiveness scale) — without invasive catheters or specialized CPAP manipulations — be validated to clinical standards (technical standardization, cutoffs, reproducibility, generalizability) for routine practice? (4) Mechanism completeness: can the physiologic contributors not quantified by the four traits — upper-airway surface tension, lung volume effects, rostral fluid shift, body-head position, hormonal influences, and ventilatory responses to transient stimuli — be systematically quantified, and can they explain why some individuals with apparently vulnerable trait combinations do not develop clinical OSA? (5) Therapeutic utility: can adequately powered, mechanism-targeted intervention trials demonstrate that PALM-based phenotyping improves patient selection for nonanatomic therapies (therapies acting on physiology rather than airway anatomy, e.g., supplemental oxygen, carbonic anhydrase inhibitors such as acetazolamide or sulthiame, hypnotics to raise the arousal threshold, hypoglossal nerve stimulation to restore dilator-muscle function) relative to unselected care? The source paper additionally anticipates that a combination of anatomic and nonanatomic interventions may ultimately be required for many patients in PALM category 2b; that anticipation remains a source-discussed hypothesis rather than part of the formal selection-utility question. These five components form one translational chain — population validity of the trait measurements, validity of the simplified measurement itself, completeness of the causal account, and demonstrated selection utility. Consistent with the surviving core identified above, the question's resolution turns on the clinical-grade standards that single-night endotype-based measurement must meet (strand 3) and on what an adequately powered, phenotype-guided selection trial would have to show — in design, endpoints and power — to establish a benefit for nonanatomic therapies (strand 5); strands 1, 2 and 4 bear on whether those standards can be met, through their implications for cutoffs, reproducibility and generalizability, and the overall question remains open despite partial progress on individual links (which already exists).

References

  1. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining Phenotypic Causes of Obstructive Sleep Apnea. Identification of Novel Therapeutic Targets. Am J Respir Crit Care Med 2013;188(8):996–1004. doi:10.1164/rccm.201303-0448oc. https://doi.org/10.1164/rccm.201303-0448oc
  2. Sands SA, Edwards BA, Terrill PI, Taranto-Montemurro L, Azarbarzin A, Marques M, Hess LB, White DP, Wellman A. Phenotyping Pharyngeal Pathophysiology using Polysomnography in Patients with Obstructive Sleep Apnea. Am J Respir Crit Care Med 2018;197(9):1187–1197. doi:10.1164/rccm.201707-1435OC. https://doi.org/10.1164/rccm.201707-1435OC
  3. Edwards BA, Sands SA, Owens RL, Eckert DJ, Landry S, White DP, Malhotra A, Wellman A. The Combination of Supplemental Oxygen and a Hypnotic Markedly Improves Obstructive Sleep Apnea in Patients with a Mild to Moderate Upper Airway Collapsibility. Sleep 2016;39(11):1973–1983. doi:10.5665/sleep.6226. https://doi.org/10.5665/sleep.6226
  4. Sands SA, Edwards BA, Terrill PI, Butler JP, Owens RL, Taranto-Montemurro L, Azarbarzin A, Marques M, Hess LB, Smales ET, de Melo CM, White DP, Malhotra A, Wellman A. Identifying obstructive sleep apnoea patients responsive to supplemental oxygen therapy. Eur Respir J 2018;52(3):1800674. doi:10.1183/13993003.00674-2018. https://doi.org/10.1183/13993003.00674-2018
  5. Gray EL, McKenzie DK, Eckert DJ. Obstructive Sleep Apnea without Obesity Is Common and Difficult to Treat: Evidence for a Distinct Pathophysiological Phenotype. J Clin Sleep Med 2017;13(1):81–88. doi:10.5664/jcsm.6394. https://doi.org/10.5664/jcsm.6394
  6. O'Driscoll DM, Landry SA, Pham J, Young A, Sands SA, Hamilton GS, Edwards BA. The physiological phenotype of obstructive sleep apnea differs between Caucasian and Chinese patients. Sleep 2019;42(11):zsz186. doi:10.1093/sleep/zsz186. https://doi.org/10.1093/sleep/zsz186
  7. Op de Beeck S, Wellman A, Dieltjens M, Strohl KP, Willemen M, Van de Heyning PH, Verbraecken JA, Vanderveken OM, Sands SA; STAR Trial Investigators. Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. Am J Respir Crit Care Med 2021;203(6):746–755. doi:10.1164/rccm.202006-2176OC. https://doi.org/10.1164/rccm.202006-2176OC
  8. Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. Am J Respir Crit Care Med 2023;208(12):1316–1327. doi:10.1164/rccm.202306-1036OC. https://doi.org/10.1164/rccm.202306-1036OC
  9. Sands SA, Collet J, Gell LK, Calianese N, Hess LB, Vena D, Azarbarzin A, Bertisch SM, Landry S, Thomson L, Joosten SA, Hamilton GS, Edwards BA. Combination pharmacological therapy targeting multiple mechanisms of sleep apnoea: a randomised controlled cross-over trial. Thorax 2024;79(3):259–268. doi:10.1136/thorax-2023-220184. https://doi.org/10.1136/thorax-2023-220184
  10. Randerath W, Grote L, Stenlöf K, Fietze I, Chevts J, Buntinx E, Albares J, Kuhn K, Hansen C, Völp A, Hedner J; FLOW study investigators. Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet 2025;406(10514):1983–1992. doi:10.1016/S0140-6736(25)01196-1. https://doi.org/10.1016/S0140-6736(25)01196-1
  11. Messineo L, Preuss M, Azarbarzin A, Vena D, Gell L, Aishah A, Esmaeili N, Kim M, Burdick I, Chen T, White D, Sands SA, Wellman A. Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity: A Randomized Crossover Trial. Chest 2025;168(1):223–235. doi:10.1016/j.chest.2025.03.013. https://doi.org/10.1016/j.chest.2025.03.013
  12. Tolbert TM, Schmickl CN, Gell LK, Keenan BT, Mazzotti DR, Op de Beeck S, Osman AM, Peña-Orbea C, Sands SA, Sofer T, Zinchuk AV, Arnardóttir ES, Azarbarzin A, Chowdhuri S, Cistulli PA, Jordan AS, Luo Y, Patel SR, Pépin JL, Redline S, Schwab RJ, Wellman A, Eckert DJ. Research Priorities for Translating Endophenotyping of Adult Obstructive Sleep Apnea to the Clinic: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2025;211(9):1562–1583. doi:10.1164/rccm.202507-1574ST. https://doi.org/10.1164/rccm.202507-1574ST
  13. Turnbull CD, Stradling JR. Endotyping, phenotyping and personalised therapy in obstructive sleep apnoea: are we there yet? Thorax 2023;78(7):726–732. doi:10.1136/thorax-2023-220037. https://doi.org/10.1136/thorax-2023-220037
  14. McNicholas WT, Op de Beeck S, Tondo P, Verbraecken J, Bonsignore MR. OSA Endotyping as Targets for Treatment. How Far Have We Come? Respirology 2026;31(4):339–351. doi:10.1002/resp.70233. https://doi.org/10.1002/resp.70233
  15. Gell LK, Bertisch SM, Lawrence NV, Gilbertson D, Calianese N, Messineo L, Vena D, Wang TY, Bakker JP, Sofer T, Martinez R, Hess LB, Azarbarzin A, Sands SA. Atomoxetine plus oxybutynin for obstructive sleep apnoea: a randomised-controlled trial with detailed pathophysiology. Thorax 2026 (online ahead of print). doi:10.1136/thorax-2025-224467. https://doi.org/10.1136/thorax-2025-224467
  16. Messineo L, Kim M, Azarbarzin A, Vena D, Preuss M, Esmaeili N, Aishah A, Lawrence NV, Gilbertson DC, White DP, Wellman A, Sands SA. Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial. Thorax 2026 (online ahead of print). doi:10.1136/thorax-2025-223922. https://doi.org/10.1136/thorax-2025-223922
  17. Wellman A, Messineo L, Azarbarzin A, Esmaeili N, Aishah A, Vena D, Sumner J, White DP, Sands SA. Oxygen-based endotypes of Obstructive Sleep Apnea. medRxiv preprint 2026. doi:10.64898/2026.06.03.26354835. https://doi.org/10.64898/2026.06.03.26354835
  18. Castro-Diehl C, Alex R, Azarbarzin A, Zhang Y, Wellman A, Huang T, Sands S, Redline S. Associations of excessive sleepiness with sleep apnea physiological endo-phenotypes: the multi-ethnic study of atherosclerosis. Ann Am Thorac Soc 2026;23(7):1067–1076. doi:10.1093/annalsats/aaoag078. https://doi.org/10.1093/annalsats/aaoag078
  19. Strassberger C, Hedner J, Sands SA, Tolbert TM, Taranto-Montemurro L, Marciniak A, Zou D, Grote L. Night-to-Night Variability of Polysomnography-Derived Physiologic Endotypic Traits in Patients With Moderate to Severe OSA. Chest 2023;163(5):1266–1278. doi:10.1016/j.chest.2022.12.029. https://doi.org/10.1016/j.chest.2022.12.029
  20. Eschbach E, Kushida C, Peker Y, Chu JH, Xu Z, Lin HM, Xu Y, Azarbarzin A, Wellman A, Yaggi HK, Sands S, Zinchuk A. Loop gain predicts residual sleep apnoea among people using positive airway pressure. Thorax 2026;81(7):694–701. doi:10.1136/thorax-2025-223878. https://doi.org/10.1136/thorax-2025-223878